Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $282.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective upped by TD Cowen from $260.00 to $282.00 in a research note published on Tuesday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also weighed in on the stock. Canaccord Genuity Group reaffirmed a buy rating and set a $283.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, June 21st. Barclays lifted their target price on Alnylam Pharmaceuticals from $236.00 to $291.00 and gave the stock an overweight rating in a research report on Tuesday. BMO Capital Markets restated an outperform rating and set a $234.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Chardan Capital reissued a buy rating and set a $225.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, May 3rd. Finally, Morgan Stanley increased their price target on shares of Alnylam Pharmaceuticals from $164.00 to $250.00 and gave the stock an equal weight rating in a research report on Tuesday. Eight investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of Moderate Buy and a consensus target price of $247.09.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $243.00 on Tuesday. The firm has a market capitalization of $30.74 billion, a price-to-earnings ratio of -90.67 and a beta of 0.30. The company’s 50 day moving average price is $159.86 and its 200 day moving average price is $164.73. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $252.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.23. The company had revenue of $494.33 million during the quarter, compared to analysts’ expectations of $428.01 million. During the same period in the previous year, the company earned ($1.40) EPS. Alnylam Pharmaceuticals’s quarterly revenue was up 54.8% on a year-over-year basis. Sell-side analysts forecast that Alnylam Pharmaceuticals will post -3.75 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, Director Amy W. Schulman sold 21,700 shares of the stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the transaction, the director now owns 8,436 shares of the company’s stock, valued at $1,253,589.60. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,301 shares of the company’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $1,917,447.99. Following the completion of the sale, the chief executive officer now directly owns 80,534 shares of the company’s stock, valued at approximately $18,602,548.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Amy W. Schulman sold 21,700 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the transaction, the director now directly owns 8,436 shares in the company, valued at approximately $1,253,589.60. The disclosure for this sale can be found here. Insiders have sold 67,357 shares of company stock valued at $13,436,711 in the last quarter. Corporate insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in ALNY. Allspring Global Investments Holdings LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 143 shares during the last quarter. Altitude Crest Partners Inc. acquired a new stake in Alnylam Pharmaceuticals during the 1st quarter worth about $30,000. Quent Capital LLC lifted its stake in Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 123 shares in the last quarter. Anchor Investment Management LLC acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $38,000. Finally, Robeco Institutional Asset Management B.V. increased its position in shares of Alnylam Pharmaceuticals by 155.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 12,513 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.